Unaudited Standalone & Consolidated Financial Results of the company for the quarter ended 30th June, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 1.0 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Genpharmasec posted strong Q1 FY26 results with standalone revenue from operations more than doubling to ₹1,211.32 lakhs from ₹530.29 lakhs in Q1 FY25 (up ~128% YoY), entirely driven by the Pharmaceuticals segment. Standalone profit after tax jumped to ₹155.92 lakhs from ₹58.87 lakhs (up ~165% YoY), with EPS of ₹0.03 versus ₹0.01. On a consolidated basis, revenue rose to ₹1,204.32 lakhs and PAT to ₹121.52 lakhs (up ~324% YoY), although the newly consolidated laboratory testing subsidiary Clinigenome India reported a ₹34.40 lakh loss. The auditor issued an unqualified review report with no qualifications. The company also noted it gained controlling interest in Derren Healthcare Pvt Ltd on 25th July 2025, a post-quarter subsequent event.
Exceptional YoY growth in both revenue and profits reflects strong scale-up in the core Pharmaceuticals business, which is positive for shareholders. However, the loss-making subsidiary Clinigenome and pending operational integration of Derren Healthcare warrant monitoring. The sharp profit growth may attract short-term investor interest, but the stock is thinly traded (micro-cap pharma), so price impact could be limited.